Increased exposure of norethindrone in HIV+ women treated with ritonavir-boosted atazanavir therapy.

ABSTRACT:

Objective

Pharmacokinetics of norethindrone in combination oral contraceptive regimen are well described among HIV+ women treated with ritonavir-boosted protease inhibitor therapies; however, such characterization is lacking in women using progestin-only contraception. Our objective is to characterize pharmacokinetics of norethindrone in HIV+ women using ritonavir-boosted atazanavir treatment during progestin-only contraceptive regimens.

Study design

An open-label, prospective, nonrandomized trial to characterize the pharmacokinetics of norethindrone in HIV+ women receiving ritonavir-boosted atazanavir (n=10; treatment group) and other antiretroviral therapy known to not alter norethindrone levels (n=17; control group) was conducted. Following informed consent, women were in

SUBMITTER: DuBois BN 

PROVIDER: S-EPMC4268426 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature